Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2024 09:54 ET | Source: Research and Markets

Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
February 08, 2024 15:17 ET | Source: Spherix Global Insights

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
November 01, 2023 14:55 ET | Source: Spherix Global Insights

Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema

Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
December 20, 2022 08:10 ET | Source: Persistence Market Research

Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$13.1 Bn by 2032 at a CAGR 1% | According PMR

New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...
July 28, 2022 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
June 03, 2022 06:58 ET | Source: Research and Markets

The Worldwide Anti-Vascular Endothelial Growth Factor Therapeutics Industry is Expected to Reach $13.3 Billion by 2030

Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...
October 17, 2012 09:15 ET | Source: Vista Partners LLC

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50

SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...
August 01, 2012 09:15 ET | Source: Vista Partners

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50

SAN FRANCISCO, CA--(Marketwire - Aug 1, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") and raised its...
April 17, 2012 09:15 ET | Source: Vista Partners LLC

Vista Partners Initiates Coverage on Ohr Pharmaceutical, Inc.; Target Price $2.20

SAN FRANCISCO, CA--(Marketwire - Apr 17, 2012) - Vista Partners announced today that it has initiated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...